Potassium-Competitive Acid Blockers (P-CABs) — AGA Clinical Practice Update 2024
Integrating P-CABs into clinical practice: mechanism, safety, and evidence-based use across GERD, H. pylori, and peptic ulcer disease
- Compare P-CABs and PPIs on mechanism, pharmacokinetics, and acid suppression potency
- Identify the clinical settings where P-CABs are recommended, may be used, or should generally not be used
- Apply all 9 AGA Best Practice Advice statements to clinical scenarios
- Recognize H. pylori eradication as the strongest evidence-based indication for P-CABs over PPIs
- Evaluate safety considerations including hypergastrinemia, C. diff risk, and long-term monitoring needs
- Counsel patients on cost and access barriers to P-CABs in the US healthcare environment
Sections
Drug class, pharmacology vs. PPIs
Potassium-competitive acid blockers (P-CABs) are a new class of antisecretory medications that reversibly inhibit the gastric H⁺/K⁺-ATPase (proton pump). Unlike PPIs — which are prodrugs requiring acid activation and covalent binding — P-CABs are acid-stable, have a faster onset, longer half-life, and are not affected by CYP2C19 polymorphisms.
1 day
Days to maximal acid suppression (vs. 3–5 days for PPIs)
6–9 h
P-CAB half-life (vs. 1–2 h for PPIs)
4–33%
PPI use prevalence in US/Europe/Australia (rising trend)
| Variable | P-CAB | PPI |
|---|---|---|
| Acid stability | Acid-stable | Acid-labile (requires enteric coating) |
| Prodrug | No — active as ingested | Yes — converted to active sulfonamide in acid |
| Pump binding | Ionic (reversible) — blocks K⁺ access | Covalent (irreversible) — binds active pump cysteines |
| Half-life | 6–9 hours | 1–2 hours |
| Meal timing | Independent of meals | 30–60 min before meals (required for efficacy) |
| Days to maximal suppression | 1 day | 3–5 days |
| CYP2C19 metabolism | Not significantly affected | Yes — CYP2C19 polymorphisms alter efficacy |
| Available examples | Vonoprazan, tegoprazan, fexuprazan, keverprazan | Omeprazole, esomeprazole, lansoprazole, pantoprazole |
Ionic, Reversible Binding
P-CABs block the potassium-binding site of H⁺/K⁺-ATPase ionically. Unlike PPIs, binding is reversible — the drug competes with K⁺ for the pump.
No Prodrug Activation Required
PPIs require acid in the secretory canaliculus to be converted to active sulfonamide. P-CABs are pharmacologically active as ingested.
Acid-Stable Pharmacokinetics
P-CABs are not degraded by gastric acid, allowing flexible dosing independent of meals — a clinically meaningful advantage.
Longer Duration of Action
Because of their longer half-lives, P-CABs remain available to bind proton pumps as they cycle, maintaining suppression over a full 24-hour period more consistently than PPIs.
CYP2C19 Independence
PPIs are metabolized by CYP2C19 — rapid metabolizers clear drug faster, reducing efficacy. P-CABs bypass this, delivering more predictable pharmacodynamics across patients.
Elevated Serum Gastrin
P-CABs raise serum gastrin to higher levels than PPIs. This is a class effect that persists during use, returning to baseline within weeks of discontinuation.
AGA Cost-Efficacy Context (BPA 1 & 2)
Despite pharmacologic advantages, P-CABs cost significantly more than PPIs in the US. Modest clinical superiority over double-dose PPIs does not justify routine first-line use given cost, limited long-term safety data, and prior authorization requirements. P-CABs should be reserved for conditions where they demonstrate clear clinical benefit.